Local treatment for an intimate problem.
Prescription vaginal estradiol delivers local treatment directly to the tissue at the center of the concern.
About 10 minutes. No charge unless your clinician approves.
Local symptoms deserve a local treatment conversation.
Estrogen decline does not only show up as hot flashes. Vaginal and urinary tissues are estrogen-responsive too, which is why menopause can bring dryness, irritation, discomfort with intimacy, urgency, and recurring urinary symptoms that seem unrelated until someone explains the biology connecting them.
Medicine has a name for that pattern: genitourinary syndrome of menopause.
This cream delivers low-dose estradiol directly to the tissue involved. Because it is applied locally, systemic absorption is lower than with oral or transdermal systemic estrogen. That is the central idea of the product: put treatment where the symptoms live, without pretending a local therapy is meant to solve systemic symptoms like hot flashes or night sweats.
The plan is usually designed to become less intrusive over time. Treatment commonly starts with more frequent application, then moves to a lower-frequency schedule set by your clinician. A calibrated applicator keeps the dose measured, and ongoing review lets the schedule follow your response rather than a generic calendar.
Treatment is applied where the tissue concern lives. Partner transfer, timing around sex, applicator use, and the difference from systemic therapy are practical questions that deserve clear answers before you begin.
Read the evidence →For symptoms too many women were taught to normalize.
Dryness Became Daily Discomfort
Burning, irritation, or dryness is no longer occasional enough to ignore. You want treatment that addresses the estrogen-responsive tissue rather than another surface moisturizer.
Intimacy Started to Hurt
Pain with sex is common in menopause and still wildly under-discussed. It is not a character test and it is not something you have to quietly accommodate forever. Local estrogen is a first-line treatment option your clinician can evaluate with you.
The Urinary Pattern Changed Too
Urgency, discomfort, or recurring infections can belong to the same estrogen-related tissue changes. When the pattern is local, it makes sense to ask whether the treatment should be local too.
Whether local estradiol belongs in your plan is determined by a licensed provider from your Assessment, sometimes alongside your existing physicians. Compounded by a licensed 503A pharmacy and not an FDA-approved drug product.
This might not be the right fit if:
- History of breast cancer or another estrogen-dependent malignancy
- Unexplained vaginal bleeding
- History of blood clots, stroke, or heart attack
- Active liver disease
- Pregnancy or planned pregnancy
Your intake screens for all contraindications. Every candidate is evaluated by a licensed clinician before any prescription is issued. No prescription is issued without clearance.
Estradiol Vaginal Cream, prescribed with care.
Compounded by a licensed 503A pharmacy. Prescribed by a licensed provider after clinical review.
- Low-dose estradiol 0.01% applied directly to vaginal tissue
- Calibrated applicator for a consistent measured dose
- Treatment typically starts more frequently and tapers to a provider-set schedule
- Lower systemic absorption than oral or transdermal systemic estrogen
- Reviewed and adjusted through your ongoing provider relationship
Prescription issued subject to provider judgment. Results vary. Not a guarantee of outcomes.
*Price reflects a 3 month commitment. Other billing options are shown at checkout.
More in Hormones & Vitality.
Estradiol Gel
Menopause symptoms should not set the pace.
Prescription estradiol gel delivers systemic estrogen through the skin in an adjustable daily format.
Estradiol Patches
Twice weekly. Steady by design.
Prescription estradiol patches provide steady transdermal delivery with a twice-weekly change schedule.
Estradiol Tablet
A familiar form, backed by serious hormone care.
Prescription oral estradiol puts established hormone therapy into a familiar, straightforward daily form.
What the research shows
More women reported improvement on estrogen cream than on placebo, on low-quality evidence.
The detail
A Cochrane review of intravaginal estrogen for vaginal atrophy pooled 30 randomized trials in 6,235 postmenopausal women treated for at least 12 weeks. For the cream specifically, more women reported improvement in symptoms on estrogen cream than on placebo, odds ratio 4.10, 95 percent confidence interval 1.88 to 8.93, from two trials with 198 women. The reviewers found no evidence of a difference in efficacy between the various intravaginal estrogen preparations, and graded the evidence low quality.1
Vaginal estrogens improved dryness, dyspareunia and urinary symptoms compared with placebo.
The detail
A systematic review conducted for the Society of Gynecologic Surgeons double-screened 1,805 abstracts and included 44 studies of vaginal estrogen for genitourinary syndrome of menopause. Compared with placebo, vaginal estrogens improved dryness, dyspareunia, urinary urgency and frequency, and stress and urgency urinary incontinence, and urinary tract infection rates decreased. Serum estradiol levels stayed within postmenopausal norms for every preparation except high-dose conjugated equine estrogen cream, and endometrial hyperplasia and adenocarcinoma were extremely rare among vaginal estrogen users.2
A lower-strength cream reduced dyspareunia severity and vaginal pH more than placebo cream.
The detail
A lower-strength estradiol vaginal cream was tested in a phase 3 randomized, double-blind, placebo-controlled trial in 550 postmenopausal women, average age 58, with moderate to severe dyspareunia as the most bothersome symptom, dosed daily for two weeks then three applications a week for 10 weeks. Against placebo cream, estradiol reduced dyspareunia severity, mean change 1.5 versus 1.2 points, lowered vaginal pH, 1.36 versus 0.53, and raised the percentage of superficial cells, 10.1 versus 1.4, all p less than 0.001, with vulvovaginal mycotic infections more frequent on estradiol.3
The approved indication and the tapering schedule are label text, not a marketing idea.
The detail
The approved indication and the tapering schedule are label text, not a marketing idea. Estradiol vaginal cream 0.01 percent is indicated for treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, and the labeled usual dosage is 2 to 4 g daily for one or two weeks, then gradually reduced to half that for a similar period, with a maintenance dose of 1 g one to three times a week once the vaginal mucosa has been restored.4
In an observational cohort, vaginal estrogen users had risks that did not differ significantly from non-users.
The detail
Longer-term safety of vaginal estrogen has been examined observationally. Among 45,663 postmenopausal women aged 50 to 79 in the Women’s Health Initiative Observational Study who used no systemic estrogen, followed a median 7.2 years, women with a uterus who used vaginal estrogen had risks of stroke, invasive breast cancer, colorectal cancer, endometrial cancer and pulmonary embolism or deep vein thrombosis that did not differ significantly from non-users, and a lower rate of the study’s composite global index event, adjusted hazard ratio 0.68, 95 percent confidence interval 0.55 to 0.86.5
What it does not show
The most rigorous placebo-controlled test of low-dose vaginal estrogen was negative.
The detail
The most rigorous placebo-controlled test of low-dose vaginal estrogen for symptoms was negative. In a 12-week multicenter randomized trial, 302 postmenopausal women with moderate to severe vulvovaginal symptoms received a vaginal 10-microgram estradiol tablet plus placebo gel, a placebo tablet plus a vaginal moisturizer, or dual placebo. Reductions in the severity of the most bothersome symptom were 1.4, 1.2 and 1.3 points respectively, and estradiol did not differ significantly from placebo, p equals 0.25. That trial tested a tablet rather than a cream, but it is a large part of why the cream evidence is graded low quality and why the honest sentence here is not that this works.16
No approved or established use for hot flashes, bone protection, cognition or longevity.
The detail
The evidence is local, and so is the indication. Approved estradiol vaginal cream labeling covers moderate to severe symptoms of vulvar and vaginal atrophy due to menopause and nothing else. It is not approved or established for hot flashes, night sweats, bone protection, cognition, cardiovascular prevention or longevity, and the trials that support systemic estradiol therapy were run on systemic products at systemic doses and do not carry over to a low-dose local cream.4
Lower systemic exposure is documented, not zero, and the safety data are observational.
The detail
Lower systemic exposure is documented, not zero, and the label still points at the class. The systematic review found serum estradiol within postmenopausal norms for the vaginal preparations studied, but the approved labeling for estradiol vaginal cream states that systemic absorption may occur and that the warnings, precautions and adverse reactions associated with oral estrogen treatment should be taken into account. The observational safety data are reassuring on their own terms and are still observational: women were not randomized to use vaginal estrogen.245
Cream labels still carry the older four-part boxed warning, and no trial tested a compounded cream.
The detail
The labeling for this dosage form has not been updated yet. On November 10, 2025 the FDA asked manufacturers of menopausal hormone therapy to remove the cardiovascular disease, breast cancer and probable dementia language from boxed warnings, and specifically asked that labeling for local vaginal formulations be condensed to prioritize the information most relevant to a local product; the first revised labels were approved on February 12, 2026, and one local vaginal estradiol product, a vaginal ring, now carries no boxed warning at all. As of August 2026 every estradiol vaginal cream label posted on DailyMed still carries the older four-part boxed warning. No trial cited here tested a compounded cream.4789
- Lethaby A, Ayeleke RO, Roberts H. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;(8):CD001500.
- Rahn DD, Carberry C, Sanses TV, et al. Vaginal estrogen for genitourinary syndrome of menopause: a systematic… Obstet Gynecol. 2014.
- Kroll R, Archer DF, Lin Y, Sniukiene V, Liu JH. A randomized, multicenter, double-blind study to evaluate the safety… Menopause. 2018.
- FDA-approved prescribing information, ESTRACE (estradiol vaginal cream USP, 0.01 percent), Allergan Inc, label version 25 published May 2024.DailyMed
- Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in… Menopause. 2018.
- Mitchell CM, Reed SD, Diem S, et al. Efficacy of vaginal estradiol or vaginal moisturizer vs placebo for… JAMA Intern Med. 2018.
- FDA-approved prescribing information, Estradiol Vaginal Cream 0.01 percent, Mylan Pharmaceuticals Inc, label version 10 published February 2026.DailyMed
- US Food and Drug Administration. FDA requests labeling changes related to safety information to clarify… Drug safety statement, November 10, 2025.FDA
- US Food and Drug Administration. FDA approves labeling changes to menopausal hormone therapy products. Press announcement, February 12, 2026.FDA
Do not use if you have
- A history of breast cancer or another estrogen-dependent cancer
- Unexplained vaginal bleeding
- A prior blood clot, stroke or heart attack
- An inherited clotting disorder
- Liver disease
- Pregnancy
Serious risks
- Endometrial cancer
- Stroke, deep vein thrombosis and pulmonary embolism
- Gallbladder disease
- Probable dementia in women who begin therapy at 65 or older
- Breast cancer when estrogen and a progestogen are taken together over longer use
Commonly reported
- Burning, irritation, or itching in the treated area
- Vaginal infection
- Vaginal bleeding or spotting
Because it is a local cream
- The approved labeling for estradiol vaginal cream states that systemic absorption can occur and that the warnings, precautions, and adverse reactions of oral estrogen therapy should be taken into account, which means the class risks stay on the table
- A local cream also does not answer the systemic question
- If you have a uterus and systemic estrogen is part of your plan, estrogen without a progestogen is not an appropriate approach, which is exactly why progesterone is part of the conversation
Bleeding you were not expecting is not something to watch and wait on, because it is the finding that prompts evaluation of the uterine lining. Most reported effects are local. Your provider decides whether local estradiol fits your history, and reviews that decision as your care continues.
Asked and answered.
You are not charged, and you are not left guessing. Your clinician explains the reasoning and, where it helps, what a better path might look like. Reviews are typically completed in under 24 hours.
Local vaginal estradiol is associated with lower systemic absorption than pills, patches, or gels, and it is used at low doses. It is still estrogen, and it is still prescription medicine: your provider reviews your history, including any cancer, clotting, or bleeding history, discusses the relevant risks with you plainly, and monitors your plan over time. Lower exposure is a fact, not a waiver.
Yes: the provider review, your prescription if approved, the medication, the applicator, shipping, and ongoing oversight, including schedule adjustments and messaging with your care team. There are no separate visit fees, and you can cancel at any time. If you are not approved, you are not charged.
Generally no, and we would rather tell you that now. Local vaginal therapy targets vaginal and urinary symptoms; systemic symptoms like hot flashes and night sweats usually call for systemic therapy. If you have both, say so in your Assessment. Some women are appropriately treated with both approaches, and that is a clinical decision made with you.